These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 9022342)
1. [Determination of malondialdehyde-modified LDL(MDA-LDL) and its potential usefulness]. Kotani K; Kondo A; Manabe M; Maekawa M; Kanno T Rinsho Byori; 1997 Jan; 45(1):47-54. PubMed ID: 9022342 [TBL] [Abstract][Full Text] [Related]
2. Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low-density lipoprotein oxidation. Maggi E; Marchesi E; Ravetta V; Martignoni A; Finardi G; Bellomo G J Hypertens; 1995 Jan; 13(1):129-38. PubMed ID: 7759843 [TBL] [Abstract][Full Text] [Related]
3. Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum. Kotani K; Maekawa M; Kanno T; Kondo A; Toda N; Manabe M Biochim Biophys Acta; 1994 Nov; 1215(1-2):121-5. PubMed ID: 7947993 [TBL] [Abstract][Full Text] [Related]
4. [Complete cholesteryl ester transfer protein deficiency increases oxidized-LDL in plasma]. Chiba H; Akita H; Kotani K; Kanno T; Manabe M Rinsho Byori; 1997 Jan; 45(1):55-7. PubMed ID: 9022343 [TBL] [Abstract][Full Text] [Related]
6. Contribution of superoxide to reduced antioxidant activity of glycoxidative serum albumin. Sakata N; Moh A; Takebayashi S Heart Vessels; 2002 Nov; 17(1):22-9. PubMed ID: 12434198 [TBL] [Abstract][Full Text] [Related]
7. The influence of platelet-smooth muscle cell interaction on the oxidative modification of low-density lipoprotein. Alexander JJ; Lewis I J Surg Res; 2002 Mar; 103(1):41-6. PubMed ID: 11855916 [TBL] [Abstract][Full Text] [Related]
8. Autoantibodies against oxidized low-density lipoprotein and C-reactive protein are associated with diabetes and myocardial infarction in women. Dotevall A; Hulthe J; Rosengren A; Wiklund O; Wilhelmsen L Clin Sci (Lond); 2001 Nov; 101(5):523-31. PubMed ID: 11672458 [TBL] [Abstract][Full Text] [Related]
9. Oxidative and malondialdehyde modification of low-density lipoprotein: a comparative study of binding and degradation by macrophages and endothelial cells. Zhou M; Chen Y; Liu S; Ding Z; Pang Z; Wan J Br J Biomed Sci; 1998 Sep; 55(3):192-8. PubMed ID: 10367404 [TBL] [Abstract][Full Text] [Related]
10. Autoantibodies to oxidized low density lipoprotein: the relationship to low density lipoprotein fatty acid composition in diabetes. Griffin ME; McInerney D; Fraser A; Johnson AH; Collins PB; Owens D; Tomkin GH Diabet Med; 1997 Sep; 14(9):741-7. PubMed ID: 9300223 [TBL] [Abstract][Full Text] [Related]
11. Oxidation of low-density lipoprotein cholesterol following administration of poloxamer 407 to mice results from an indirect effect. Johnston TP; Zhou X J Cardiovasc Pharmacol; 2007 Apr; 49(4):246-52. PubMed ID: 17438410 [TBL] [Abstract][Full Text] [Related]
12. Malondialdehyde-modified low-density lipoproteins as biomarker for atherosclerosis. Viigimaa M; Abina J; Zemtsovskaya G; Tikhaze A; Konovalova G; Kumskova E; Lankin V Blood Press; 2010 Jun; 19(3):164-8. PubMed ID: 20429692 [TBL] [Abstract][Full Text] [Related]
13. Generation and characterization of IgG monoclonal antibodies specific for malondialdehyde. Choi JW; Kim DJ; Rhim JH; Chung JH; Chung HK Hybrid Hybridomics; 2003 Aug; 22(4):259-62. PubMed ID: 14511571 [TBL] [Abstract][Full Text] [Related]
14. [Changes in serum malondialdehyde-modified low-density lipoprotein in patients with acute myocardial infarction and stable angina pectoris treated by coronary angioplasty]. Araki T; Kanaya H; Shimizu M; Mabuchi H; Kitayama M; Kanemitsu S; Takekoshi N; J Cardiol; 2001 Aug; 38(2):55-60. PubMed ID: 11525110 [TBL] [Abstract][Full Text] [Related]
15. Increase in plasma malondialdehyde-modified low-density lipoprotein in patients with atherothrombotic cerebral infarction. Kametsu Y; Kitagawa Y; Sekiyama S; Takagi S Tokai J Exp Clin Med; 2005 Sep; 30(3):171-6. PubMed ID: 16285608 [TBL] [Abstract][Full Text] [Related]
16. Autoantibodies to malondialdehyde-modified low-density lipoprotein in patients with angiographically confirmed coronary artery disease. McDowell A; Young IS; Wisdom GB J Pharm Pharmacol; 2002 Dec; 54(12):1651-7. PubMed ID: 12542895 [TBL] [Abstract][Full Text] [Related]
17. Gold nanoparticle-antibody conjugates for specific extraction and subsequent analysis by liquid chromatography-tandem mass spectrometry of malondialdehyde-modified low density lipoprotein as biomarker for cardiovascular risk. Haller E; Lindner W; Lämmerhofer M Anal Chim Acta; 2015 Feb; 857():53-63. PubMed ID: 25604820 [TBL] [Abstract][Full Text] [Related]
18. Low density lipoprotein oxidation and atherogenesis: from experimental models to clinical studies. Napoli C G Ital Cardiol; 1997 Dec; 27(12):1302-14. PubMed ID: 9470066 [TBL] [Abstract][Full Text] [Related]
19. Specific recognition of malondialdehyde and malondialdehyde acetaldehyde adducts on oxidized LDL and apoptotic cells by complement anaphylatoxin C3a. Veneskoski M; Turunen SP; Kummu O; Nissinen A; Rannikko S; Levonen AL; Hörkkö S Free Radic Biol Med; 2011 Aug; 51(4):834-43. PubMed ID: 21683785 [TBL] [Abstract][Full Text] [Related]
20. [Inhibitory effect of paeonol on lipid peroxidational reaction and oxidational decorate of low density lipoprotein]. Dai M; Liu QY; Gu CG; Zhang HY Zhongguo Zhong Yao Za Zhi; 2000 Oct; 25(10):625-7. PubMed ID: 12516456 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]